Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | RAF1 | P04049 | 2/20 | 0.53 |
| ▸ | KDR | P35968 | 3/20 | 0.52 |
| ▸ | LCLAT1 | Q6UWP7 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 2/20 | 0.48 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5419618 | 0.90 | RAF1 (0.57) | DDR2MAPK1KMT2AMEN1RAF1 | |
| SCHEMBL5429857 | 0.89 | KMT2A (0.54) | DDR2KMT2AMEN1RAF1KDR | |
| SCHEMBL5426233 | 0.88 | KCNMA1 (0.56) | DDR2RAF1KDRRETBRAF | |
| SCHEMBL5422540 | 0.87 | RAF1 (0.60) | KMT2AMEN1RAF1KDRBRAF | |
| SCHEMBL5425435 | 0.86 | KDR (0.54) | DDR2RAF1KDRRETBRAF | |
| SCHEMBL5419926 | 0.86 | RAF1 (0.72) | DDR2RAF1KDRRET | |
| SCHEMBL14527433 | 0.86 | KDR (0.50) | DDR2KMT2AMEN1RAF1KDR | |
| SCHEMBL13648232 | 0.84 | DDR2 (0.61) | DDR2MAPK1KMT2AMEN1RAF1 | |
| SCHEMBL14488822 | 0.84 | KDR (0.69) | DDR2MAPK1KMT2AMEN1RAF1 | |
| SCHEMBL4473374 | 0.83 | DDR2 (0.54) | DDR2MAPK1KMT2AMEN1RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142440-A1 | Pyridinamide derivatives as kinase inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2007-06-21 | — | — | US | claimed |
| US-20070142440-A1 | Pyridinamide derivatives as kinase inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142440-A1 | Pyridinamide derivatives as kinase inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142440-A1 | Pyridinamide derivatives as kinase inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142440-A1 | Pyridinamide derivatives as kinase inhibitors | TIE1, KDR, FLT1 | DDR2 273/4885MAPK1 112/4885KMT2A 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.